| Lung Non-Small Cell Squamous Carcinoma studied in …STUDIED_INderived25 of 25show fewer |
|---|
| → studied in | NCT04267848Phase 3 · recruiting Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · condition mapped ONTOLOGY_EXACT · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07489066Phase 2 · recruiting Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC · condition mapped ALIAS · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03965689Phase 2 · active not recruiting Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216316Phase 1/Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02955290Phase 1/Phase 2 · active not recruiting CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06222489Phase 2 · recruiting Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256290Phase 1/Phase 2 · active not recruiting Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05873686Phase 1 · recruiting A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers · condition mapped ALIAS · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03110978Phase 2 · active not recruiting Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06051695Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression · condition mapped ALIAS · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06463665Phase 2 · recruiting Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05865990Phase 2 · completed HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05613413Phase 2 · recruiting A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05652868Phase 1 · terminated Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05086692Phase 1/Phase 2 · recruiting A Beta-only IL-2 ImmunoTherapY Study · condition mapped ALIAS · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03845296Phase 2 · completed Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) · condition mapped ONTOLOGY_EXACT · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05736731Phase 1/Phase 2 · active not recruiting A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression · condition mapped ALIAS · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04032704Phase 2 · terminated A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors · condition mapped ALIAS · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06037733NA · recruiting Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06207292NA · unknown Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer · condition mapped ALIAS · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05127590Phase 1/Phase 2 · unknown RBN-2397 in Combination With Pembrolizumab in Patients With SCCL · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05718167Phase 3 · unknown TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05207904Phase 2 · unknown Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases · condition mapped ALIAS · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04846452Phase 2 · unknown Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC · condition mapped CURATED_BROADER · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03811652Phase 1 · completed A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 25 trials mapped (15 active) | — | — | Lung Non-Small Cell Squamous Carcinoma | 1 | Observed | clinicaltrials | graph → |